Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (591)	1/17/2002 2:46:21 AM
From: nigel bates	Read Replies (1) \| Respond to of 1005

I don't suppose anyone here aside from George watches Aclara Only in a desultory manner. This yesterday - MOUNTAIN VIEW, Calif., Jan. 16 /PRNewswire-FirstCall/ -- ACLARA BioSciences (Nasdaq: ACLA - news) announced that the company is collaborating with Dr. P.J. Utz, Assistant Professor of Medicine, and Dr. William Robinson, both at the Stanford University School of Medicine, to apply ACLARA's eTag technology for proteomics research. In particular, the Stanford researchers plan to characterize serum autoantibody profiles in a variety of autoimmune diseases, with the objective of developing "immunology proteome" panels for use in drug discovery, clinical medicine and academic research. Dr. Utz explained, ``I am very interested in the potential of ACLARA's eTag technology for profiling autoantibodies. One particularly enabling feature of the eTag technology is that the assay is performed in solution phase, and thus it is not necessary to immobilize the antigen probes onto a bead or glass surface. We believe that this feature may dramatically expand the set of antigens that we can incorporate into our multiplexed immunology panels.'' Joseph M. Limber, ACLARA's President and CEO, commented, ``ACLARA's collaboration with Drs. Utz and Robinson represents an important component of our eTag commercialization strategy. We believe that eTag immunology panels could be highly enabling in pharmaceutical research and clinical diagnostics. As in this collaboration, we intend to work with innovators in different areas of life science research to establish eTags as the gold standard for multiplexing in genotyping, gene expression and proteomics.'' Dr. Utz and collaborators at Stanford have embarked on a major effort to understand the autoantibody response in autoimmunity. As part of this effort, these researchers intend to identify patterns of antigens that are recognized by unique autoantibodies present in the serum of patients with autoimmune disease and other illnesses such as infectious diseases. A panel of antigens will be used to probe for and profile the levels of specific autoantibodies in each biological sample, including serum, synovial fluid, and cerebrospinal fluid. Because of the large number of antigens, these studies require a technology capable of simultaneously measuring many antigen-antibody reactions in a small sample...